As reported in the Journal of Clinical Oncology by Chesney et al, the phase III MASTERKEY-265 trial has shown no significant improvement in progression-free survival or overall survival with the addition of talimogene laherparepvec (T-VEC) to pembrolizumab in patients with advanced melanoma.
Clinical Trials
Enrollment Begins in Phase 2 Trial of Rintatolimod in PD-1/PD-L1 Resistant Melanoma
Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.
Atezolizumab Triplet Induces Intracranial Responses in BRAF V600-Mutated Metastatic Melanoma
In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.
Phase 1 Trial of Darovasertib Monotherapy Enrolls First Patient With Uveal Melanoma
A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.